It is time for In Vivo's 15th annual Deals of the Year contest. We've selected 15 nominees across three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners.

Cipla set to hold 10.35% in biotech Ethris, which is progressing inhaled mRNA-based therapies, among other key assets. The Indian firm expects its next wave of growth to come from areas like biosimilars and mRNA alongside lung leadership aspirations, putting the spotlight on the broader direction of the deal.

The Canadian firm’s bispecific antibody asset improved response rates in advanced biliary tract cancer patients, potentially setting it up to become the first HER2-targeted drug approved for the disease.

Improvements in generating, purifying, and delivering RNA material, as well as addressing challenges with degradation by enzymes, have made the RNA class more attractive to drug developers.